

Jan A Burger

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/5352342/publications.pdf](https://exaly.com/author-pdf/5352342/publications.pdf)

Version: 2025-02-01

200
papers

21,974
citations

6267

75
h-index

6586

147
g-index

211
all docs

211
docs citations

211
times ranked

16848
citing authors

#	ARTICLE	IF	CITATIONS
1	A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. <i>Blood Advances</i> , 2024, 8, 2342-2350.	5.3	6
2	T-bet suppresses proliferation of malignant B cells in chronic lymphocytic leukemia. <i>Blood</i> , 2024, 144, 510-524.	1.0	2
3	Deuterated water labeling in ibrutinib-treated patients with CLL: leukemia cell kinetics correlate with κ IGHV, ZAP-70, and MRD. <i>Blood</i> , 2024, 144, 2678-2681.	1.0	1
4	A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL. <i>Blood Advances</i> , 2023, 7, 1958-1966.	5.3	43
5	Phase I Results of Bromodomain and Extra-Terminal Inhibitor PLX51107 in Combination with Azacitidine in Patients with Relapsed/Refractory Myeloid Malignancies. <i>Clinical Cancer Research</i> , 2023, 29, 4352-4360.	6.4	6
6	B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. <i>Journal of Clinical Investigation</i> , 2022, 132, .	9.1	11
7	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. <i>Leukemia and Lymphoma</i> , 2022, 63, 1375-1386.	1.6	12
8	Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurse-like cell co-cultures. <i>Leukemia</i> , 2022, 36, 1324-1335.	8.1	10
9	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. <i>Blood Cancer Journal</i> , 2022, 12, .	5.9	10
10	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. <i>Blood Advances</i> , 2022, 6, 3440-3450.	5.3	147
11	Zanubrutinib for treatment-naïve and relapsed/refractory chronic lymphocytic leukaemia: long-term follow-up of the phase I/II AURA study. <i>British Journal of Haematology</i> , 2022, 196, 1209-1218.	2.7	29
12	Molecular map of chronic lymphocytic leukemia and its impact on outcome. <i>Nature Genetics</i> , 2022, 54, 1664-1674.	16.3	78
13	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. <i>Leukemia</i> , 2021, 35, 2621-2634.	8.1	18
14	The multi-kinase inhibitor TGO2 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. <i>Blood Cancer Journal</i> , 2021, 11, .	5.9	14
15	Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2021, 102, 106520.	0.6	32
16	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. <i>Blood Advances</i> , 2021, 5, 1876-1883.	5.3	63
17	CLL cells are moved by the MARCKS brothers. <i>Blood</i> , 2021, 138, 503-504.	1.0	1
18	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. <i>Leukemia</i> , 2021, 35, 3163-3175.	8.1	31

#	ARTICLE	IF	CITATIONS
19	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. <i>Leukemia</i> , 2021, 35, 3421-3429.	8.1	25
20	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 61-68.	2.7	3
21	Resistance Mutations to BTK Inhibitors Originate From the NF- κ B but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. <i>Frontiers in Immunology</i> , 2021, 12, .	5.0	36
22	Integrating New Therapies for Chronic Lymphocytic Leukemia. <i>Cancer Journal (Sudbury, Mass)</i> , 2021, 27, 275-285.	1.9	4
23	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. <i>JAMA Oncology</i> , 2021, 7, 1213.	13.6	66
24	Ibrutinib induces durable remissions in treatment-naïve patients with CLL and 17p deletion and/or TP53 mutations. <i>Blood</i> , 2021, 138, 2589-2592.	1.0	20
25	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. <i>Leukemia</i> , 2021, 36, 712-722.	8.1	5
26	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2020, 7, e724-e736.	9.6	219
27	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2020, 97, 106432.	0.6	46
28	Treatment of Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 460-473.	25.5	174
29	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. <i>Annals of Hematology</i> , 2020, 99, 2343-2349.	1.6	3
30	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. <i>Journal of Clinical and Experimental Hematopathology: JCEH</i> , 2020, 60, 130-137.	1.2	3
31	Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. <i>Leukemia and Lymphoma</i> , 2020, 61, 2536-2537.	1.6	14
32	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. <i>Clinical Cancer Research</i> , 2020, 26, 3918-3927.	6.4	133
33	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2020, 35, 1610-1620.	8.1	17
34	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. <i>Blood</i> , 2020, 136, 42-43.	1.0	12
35	Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. <i>Blood</i> , 2020, 135, 510-513.	1.0	12
36	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). <i>Blood</i> , 2020, 136, 25-26.	1.0	4

#	ARTICLE	IF	CITATIONS
37	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. <i>Blood</i> , 2019, 134, 851-859.	1.0	278
38	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3461-3469.	1.6	21
39	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. <i>British Journal of Haematology</i> , 2019, 187, .	2.7	4
40	Association of gene mutations with time to first treatment in 384 treatment-naive chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2019, 187, 307-318.	2.7	25
41	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019, 94, 1353-1363.	6.3	342
42	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. <i>Blood</i> , 2019, 134, 1811-1820.	1.0	67
43	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. <i>Lancet Haematology</i> , 2019, 6, e100-e109.	9.6	61
44	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. <i>Blood</i> , 2019, 133, 2031-2042.	1.0	183
45	Routine sequencing in CLL has prognostic implications and provides new insight into pathogenesis and targeted treatments. <i>British Journal of Haematology</i> , 2019, 185, 852-864.	2.7	19
46	Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. <i>Clinical Cancer Research</i> , 2019, 25, 2372-2374.	6.4	0
47	Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. <i>British Journal of Haematology</i> , 2019, 186, 175-180.	2.7	9
48	Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 2056-2068.	1.0	15
49	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019, 186, 184-188.	2.7	12
50	Outcomes with ibrutinib by line of therapy and post-ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. <i>American Journal of Hematology</i> , 2019, 94, 554-562.	6.3	28
51	Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. <i>Blood</i> , 2019, 134, 1951-1959.	1.0	45
52	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. <i>Blood Advances</i> , 2019, 3, 1799-1807.	5.3	96
53	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. <i>Blood Advances</i> , 2019, 3, 1533-1539.	5.3	12
54	Bruton Tyrosine Kinase Inhibitors. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 386-393.	1.9	123

#	ARTICLE	IF	CITATIONS
55	A phase II trial of eltrombopag for patients with chronic lymphocytic leukaemia (CLL) and thrombocytopenia. <i>British Journal of Haematology</i> , 2019, 185, 606-608.	2.7	7
56	Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. <i>American Journal of Hematology</i> , 2019, 94, .	6.3	22
57	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , 2019, 184, 558-569.	2.7	75
58	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2019, 133, 1011-1019.	1.0	170
59	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. <i>Leukemia and Lymphoma</i> , 2019, 60, 1000-1005.	1.6	22
60	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. <i>Leukemia</i> , 2019, 34, 787-798.	8.1	328
61	The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. <i>Leukemia</i> , 2019, 34, 1588-1598.	8.1	17
62	Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2018, 32, 2278-2281.	8.1	3
63	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. <i>Blood</i> , 2018, 131, 1910-1919.	1.0	325
64	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. <i>Nature Reviews Cancer</i> , 2018, 18, 148-167.	24.2	304
65	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. <i>Blood</i> , 2018, 131, 1820-1832.	1.0	41
66	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. <i>Oncolimmunology</i> , 2018, 7, .	5.6	9
67	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. <i>Journal of Experimental Medicine</i> , 2018, 215, 681-697.	8.1	66
68	New pieces in the BTKi resistance puzzle. <i>Blood</i> , 2018, 131, 1995-1996.	1.0	0
69	Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. <i>British Journal of Haematology</i> , 2018, 180, 597-600.	2.7	5
70	Duvelisib, a novel oral dual inhibitor of PI3K-Î³, is clinically active in advanced hematologic malignancies. <i>Blood</i> , 2018, 131, 877-887.	1.0	210
71	Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 31-42.	4.1	57
72	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. <i>Leukemia</i> , 2018, 32, 2388-2398.	8.1	31

#	ARTICLE	IF	CITATIONS
73	Evolution of CLL treatment “ from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews Clinical Oncology, 2018, 15, 510-527.	25.3	107
74	Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 648-657.e15.	0.6	60
75	Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies. American Journal of Hematology, 2018, 93, 1402-1410.	6.3	21
76	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	4.3	107
77	Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine, 2018, 109, 11-16.	3.5	71
78	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia, 2018, 33, 287-298.	8.1	44
79	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight, 2018, 3, .	5.5	40
80	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. Journal of Immunology, 2017, 198, 1740-1747.	0.6	88
81	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research, 2017, 23, 1149-1155.	6.4	52
82	Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer, 2017, 123, 2268-2273.	4.4	97
83	HSP90, a chaperone that can make you SYK. Blood, 2017, 129, 542-544.	1.0	1
84	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with single-agent ibrutinib. British Journal of Haematology, 2017, 178, 286-291.	2.7	57
85	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 2017, 129, 2612-2615.	1.0	115
86	Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood, 2017, 129, 1155-1165.	1.0	67
87	Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica, 2017, 102, e494-e496.	4.3	7
88	CLL progression after one cycle of FCR: Richter's transformation versus EBV-associated lymphoma proliferation. American Journal of Hematology, 2017, 92, 1113-1114.	6.3	6
89	Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica, 2017, 102, e394-e396.	4.3	8
90	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 2017, 102, 1796-1805.	4.3	208

#	ARTICLE	IF	CITATIONS
91	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2154-2158.	6.4	49
92	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , 2017, 23, 2313-2324.	6.4	48
93	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. <i>Nature Communications</i> , 2017, 8, .	14.1	141
94	Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. <i>JCI Insight</i> , 2017, 2, .	5.5	76
95	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. <i>Oncotarget</i> , 2016, 7, 65968-65981.	1.7	83
96	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in B-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 425-436.	2.7	30
97	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. <i>Haematologica</i> , 2016, 101, e254-e258.	4.3	36
98	Obinutuzumab: the more the merrier?. <i>Blood</i> , 2016, 127, 6-8.	1.0	3
99	Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, e295-e298.	4.3	64
100	Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. <i>Journal of Immunology</i> , 2016, 197, 2522-2531.	0.6	34
101	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. <i>Nature Communications</i> , 2016, 7, .	14.1	277
102	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1077-1089.	2.3	12
103	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. <i>Clinical Cancer Research</i> , 2016, 22, 2359-2367.	6.4	22
104	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. <i>Leukemia and Lymphoma</i> , 2016, 57, 563-571.	1.6	31
105	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 401-413.	3.6	175
106	The addition of CD20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy – the MD Anderson Cancer Center experience. <i>British Journal of Haematology</i> , 2015, 171, 281-284.	2.7	5
107	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 2915-2922.	1.0	94
108	A phase 2 study of idelalisib plus rituximab in treatment-naïve older patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 126, 2686-2694.	1.0	216

#	ARTICLE	IF	CITATIONS
109	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. <i>Cancer</i> , 2015, 121, 3612-3621.	4.4	211
110	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , 2015, 171, 726-735.	2.7	51
111	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 373, 2425-2437.	25.5	1,241
112	The importance of the tissue microenvironment in hairy cell leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2015, 28, 208-216.	1.9	11
113	Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the BTK inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2015, 170, 125-128.	2.7	11
114	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	33.4	108
115	Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 385-391.	0.6	26
116	Secondary mutations as mediators of resistance to targeted therapy in leukemia. <i>Blood</i> , 2015, 125, 3236-3245.	1.0	119
117	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. <i>Blood</i> , 2015, 125, 2497-2506.	1.0	570
118	PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). <i>Current Topics in Microbiology and Immunology</i> , 2015, , 123-142.	0.0	45
119	Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions. <i>Blood</i> , 2015, 126, 1737-1737.	1.0	7
120	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. <i>Seminars in Cancer Biology</i> , 2014, 24, 71-81.	14.2	237
121	Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemia—Focus on the B-Cell Receptor. <i>Clinical Cancer Research</i> , 2014, 20, 548-556.	6.4	70
122	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. <i>Lancet Oncology</i> , The, 2014, 15, 48-58.	21.9	387
123	The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. <i>British Journal of Haematology</i> , 2014, 166, 177-188.	2.7	63
124	Idelalisib targeting PI3K in patients with B-cell malignancies. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 184-186.	25.3	44
125	The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. <i>Blood</i> , 2014, 123, 1032-1039.	1.0	184
126	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1090-1099.	21.9	281

#	ARTICLE	IF	CITATIONS
127	Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13906-13911.	7.7	84
128	Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. , 2014, 144, 338-348.		49
129	CD49d Is the Strongest Flow Cytometry-Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2014, 32, 897-904.	17.1	154
130	Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. Journal of Clinical Oncology, 2014, 32, 1830-1839.	17.1	98
131	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood, 2014, 123, 4132-4135.	1.0	87
132	Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood, 2014, 123, 3797-3802.	1.0	56
133	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. Blood, 2014, 124, 1990-1990.	1.0	10
134	Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-Naïve Patients ≥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2014, 124, 1994-1994.	1.0	19
135	Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma. Blood, 2014, 124, 326-326.	1.0	10
136	B cell receptor signaling in chronic lymphocytic leukemia. Trends in Immunology, 2013, 34, 592-601.	15.9	274
137	Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 584-591.	17.1	123
138	The CLL Cell Microenvironment. Advances in Experimental Medicine and Biology, 2013, , 25-45.	0.0	18
139	Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood, 2013, 121, 1501-1509.	1.0	97
140	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leukemia and Lymphoma, 2013, 54, 2385-2391.	1.6	134
141	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2013, 369, 32-42.	25.5	1,903
142	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. PLoS ONE, 2013, 8, e83830.	2.5	74
143	Bruton's Tyrosine Kinase (BTK) Inhibitors in Clinical Trials. Current Hematologic Malignancy Reports, 2013, 9, 44-49.	3.1	84
144	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 1630-1630.	1.0	26

#	ARTICLE	IF	CITATIONS
145	Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. <i>Blood</i> , 2013, 122, 525-525.	1.0	27
146	The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. <i>Expert Opinion on Medical Diagnostics</i> , 2012, 6, 49-57.	2.1	4
147	Targeting CXCR4 in Chronic Lymphocytic Leukemia: Preclinical Rationale and Early Clinical Experience. , 2012, , 369-385.		0
148	Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. <i>Current Opinion in Oncology</i> , 2012, 24, 643-649.	2.3	55
149	Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. <i>Haematologica</i> , 2012, 97, 599-607.	4.3	61
150	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. <i>Blood</i> , 2012, 119, 1182-1189.	1.0	538
151	Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. <i>Leukemia and Lymphoma</i> , 2012, 53, 3-4.	1.6	1
152	Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. <i>Nature Cell Biology</i> , 2012, 14, 276-286.	10.5	304
153	The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. <i>Blood</i> , 2012, 120, 187-187.	1.0	24
154	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. <i>Blood</i> , 2012, 120, 189-189.	1.0	27
155	Cell Trafficking in Chronic Lymphocytic Leukemia. <i>Open Journal of Hematology</i> , 2012, 3, 1.	0.0	58
156	The Bone Marrow Microenvironment and Its Impact in Acute and Chronic B Cell Malignancies. , 2012, , 35-45.		0
157	The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. <i>Leukemia and Lymphoma</i> , 2011, 52, 94-98.	1.6	14
158	CCL3 (MIP-1 α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2011, 117, 1662-1669.	1.0	109
159	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011, 118, 3489-3498.	1.0	146
160	The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies. <i>Seminars in Cancer Biology</i> , 2011, 21, 308-312.	14.2	48
161	Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2011, 29, 4088-4095.	17.1	113
162	Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2011, 2011, 96-103.	3.0	140

#	ARTICLE	IF	CITATIONS
163	Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 621-630.	2.6	78
164	The phosphoinositide 3-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood, 2011, 118, 3603-3612.	1.0	454
165	Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2011, 7, 26-33.	3.1	45
166	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors. Blood, 2011, 118, 1760-1760.	1.0	9
167	Phosphoinositide 3-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia. Oncotarget, 2011, 2, 737-738.	1.7	14
168	Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood, 2010, 116, 1083-1091.	1.0	50
169	Angiopoietin-2 in CLL. Blood, 2010, 116, 508-509.	1.0	8
170	Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Seminars in Cancer Biology, 2010, 20, 424-430.	14.2	89
171	The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2010, 28, e732-e734.	17.1	11
172	BCR-Mediated Decrease of CXCR4 and CD62L in CLL Letter. Cancer Research, 2010, 70, 5194-5194.	0.6	5
173	Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2450-2450.	1.0	22
174	Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.. Blood, 2010, 116, 45-45.	1.0	8
175	The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase I Studies. Blood, 2010, 116, 57-57.	1.0	20
176	CXCR4 in acute myelogenous leukemia (AML): When too much attraction is bad for you. Leukemia Research, 2009, 33, 747-748.	0.6	7
177	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood, 2009, 114, 4441-4450.	1.0	273
178	The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood, 2009, 114, 3367-3375.	1.0	448
179	AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood, 2009, 113, 149-153.	1.0	131
180	Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood, 2009, 113, 4604-4613.	1.0	156

#	ARTICLE	IF	CITATIONS
181	Isoform-selective phosphoinositide 3-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. <i>Blood</i> , 2009, 113, 5549-5557.	1.0	124
182	High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurse-like cell cocultures and after BCR stimulation. <i>Blood</i> , 2009, 113, 3050-3058.	1.0	263
183	The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. <i>Blood</i> , 2009, 114, 2560-2561.	1.0	22
184	B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. <i>Blood</i> , 2009, 114, 1029-1037.	1.0	194
185	CXCR4 is a prognostic marker in acute myelogenous leukemia. <i>Blood</i> , 2007, 109, 786-791.	1.0	266
186	Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2007, 110, 3316-3325.	1.0	192
187	Fledgling prognostic markers in CLL. <i>Blood</i> , 2007, 110, 3820-3821.	1.0	1
188	No cell is an island unto itself: The stromal microenvironment in chronic lymphocytic leukemia. <i>Leukemia Research</i> , 2007, 31, 887-888.	0.6	6
189	The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. <i>British Journal of Haematology</i> , 2007, 137, 288-296.	2.7	140
190	CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. <i>Blood</i> , 2006, 107, 1761-1767.	1.0	1,004
191	Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2006, 47, 2427-2430.	1.6	3
192	Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005, 106, 1824-1830.	1.0	256
193	CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. <i>Oncogene</i> , 2005, 24, 4462-4471.	6.6	230
194	CXCR4 chemokine receptors (CD184) and $\alpha 4 \beta 1$ integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). <i>British Journal of Haematology</i> , 2003, 122, 579-589.	2.7	68
195	Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. <i>Oncogene</i> , 2003, 22, 8093-8101.	6.6	230
196	Distinctive features of "nurse-like" cells that differentiate in the context of chronic lymphocytic leukemia. <i>Blood</i> , 2002, 99, 1030-1037.	1.0	215
197	Chemokine Receptors and Stromal Cells in the Homing and Homeostasis of Chronic Lymphocytic Leukemia B Cells. <i>Leukemia and Lymphoma</i> , 2002, 43, 461-466.	1.6	125
198	Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cell-derived factor-1 and CD106 (VCAM-1)-dependent mechanism. <i>Journal of Clinical Investigation</i> , 2001, 107, 305-315.	9.1	155

#	ARTICLE	IF	CITATIONS
199	Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. <i>Blood</i> , 2000, 96, 2655-2663.	1.0	626
200	Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells. <i>Blood</i> , 1999, 94, 3658-3667.	1.0	421